BioSpring Breaks Ground on One of World’s Largest Nucleic Acid API Sites in Germany

• BioSpring has broken ground on a major new GMP manufacturing site in Offenbach, Germany, focused on DNA- and RNA-based APIs.

• The facility will cover over 15,200 m² and employ around 200 staff, with completion planned by the end of 2027.

BioSpring has officially launched construction of a major new manufacturing site on the Offenbach Innovation Campus in Germany, in a move that will position the company among the world’s largest producers of DNA- and RNA-based active pharmaceutical ingredients (APIs).

The new facility, which is expected to be completed by the end of 2027, will span over 15,200 square metres and create approximately 200 jobs. Built to GMP standards, the plant will include manufacturing and warehouse units, quality control areas, offices, and a dedicated solvent tank farm.

“This allows us to support our clients’ growth by offering new high-volume capacity,” said Dr. Sylvia Wojczewski, CEO of BioSpring. “The investment underscores our position as a global leading industrial manufacturer of synthetic nucleic acids.”

The expansion was welcomed by regional leaders, including Hesse’s Minister President Boris Rhein and Offenbach Mayor Dr. Felix Schwenke, who highlighted BioSpring’s role in supporting the region’s biotech ecosystem. The company confirmed it plans further job creation at the site in the future.

With nearly 30 years of experience, BioSpring specialises in the manufacturing and analysis of therapeutic nucleic acids, supporting a wide range of therapeutic areas including oncology, neurodegeneration, and rare genetic disorders.